Objective:

To explore how AI can enhance drug discovery and development for rare diseases.

Key Findings:

• AI can significantly accelerate drug development for rare diseases by enabling better data analysis.
• Early identification of rare diseases through AI can lead to timely interventions and improved patient outcomes.
• The cost of developing orphan drugs remains high, but regulatory incentives exist to encourage development.

Interpretation:

AI has the potential to transform rare disease drug discovery by overcoming existing challenges in data access, symptom recognition, and regulatory processes.

Limitations:

• Data scarcity and fragmentation continue to hinder comprehensive analysis.
• High costs and long timelines for drug development remain significant barriers.

Conclusion:

AI represents a promising avenue for enhancing the efficiency and effectiveness of drug discovery for rare diseases, though challenges remain.